What 4 Analyst Ratings Have To Say About Phreesia
Phreesia (NYSE:PHR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 2 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 2 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Phreesia, revealing an average target of $33.0, a high estimate of $35.00, and a low estimate of $28.00. This current average has increased by 3.94% from the previous average price target of $31.75.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive Phreesia. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Aleksey Yefremov | Keybanc | Raises | Overweight | $35.00 | $28.00 |
Jailendra Singh | Truist Securities | Raises | Buy | $35.00 | $34.00 |
Richard Close | Canaccord Genuity | Lowers | Buy | $34.00 | $35.00 |
Scott Schoenhaus | Keybanc | Lowers | Overweight | $28.00 | $30.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Phreesia. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Phreesia compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Phreesia's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Phreesia's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Phreesia analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Phreesia's Background
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
Phreesia's Economic Impact: An Analysis
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Phreesia displayed positive results in 3M. As of 30 April, 2025, the company achieved a solid revenue growth rate of approximately 14.54%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.38%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Phreesia's ROE excels beyond industry benchmarks, reaching -1.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.99%, the company showcases effective utilization of assets.
Debt Management: Phreesia's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.06.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for PHR
Date | Firm | Action | From | To |
---|---|---|---|---|
Jan 2022 | SVB Leerink | Downgrades | Outperform | Market Perform |
Dec 2021 | Raymond James | Maintains | Outperform | |
Dec 2021 | SVB Leerink | Maintains | Outperform |
Posted-In: BZI-AARAnalyst Ratings